CELONKO – "Development of modern biomarkers and development of an innovative FGFR kinases inhibitor"
– the project received co-financing from the National Centre for Research and Development in the amount of PLN 39,025,710 under THE PROGRAMME OF SCIENTIFIC RESEARCH AND DEVELOPMENT entitled STRATEGMED “PROPHYLAXYS AND TREATMENT OF DISEASES OF AFFLUENCE”.
For many years Celon Pharma has been developing projects targeting selected cancer paths. CELONKO, with its objective being preclinical and clinical development of a new anti-cancer drug targeting fibroblast growth factor receptors (FGFRs), fits well into this scope of activities. As a result of R&D works, a selective, small-molecule FGFR inhibitor will be obtained. It will be possible to use this drug in the fight against stomach cancer, bladder cancer and in treatment of squamous cell lung cancer. Subsequent stages of the project will include the development of a diagnostic test for identifying patients with FGFR receptor aberrations. This will allow for selecting the patients who would benefit most from a personalised therapy based on a selective FGFR inhibitor.
The project is implemented by a scientific-business consortium led by Celon Pharma along with the National Research Institute for Tuberculosis and Lung Diseases in Warsaw, the Military Institute of Medicine in Warsaw, the Maria Skłodowska-Curie Institute of Oncology in Warsaw and the Medical University of Gdańsk. The scientific institutions are responsible for the search for molecular pathways and diagnostic methods and their facilities will also carry out the clinical part of the project. Celon Pharma, as the consortium leader, is responsible for the issues related to regulation, quality and pharmaceutical aspects, as well as coordination of clinical trials conducted with the objective of obtaining the FGFR inhibitor.
Total value of the project: PLN 54,717125